New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of ...

Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any ...

Simple math illustrates the challenge facing U.S. taxpayers, consumers and insurers following the launch late last year of two expensive new drugs to treat hepatitis C. If all 3 million people ...

The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.

Researchers from the University of Texas MD Anderson Cancer Center in Houston have found the cost of treating people with hepatitis C virus with newly approved therapies may cost the country’s health ...

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping ...